Announcements

09DEC

Semi-Annual Reconstitution (Preliminary) - December 2024

Please see attached PDF file for the preliminary changes to the LifeSci Biotechnology Clinical Trials Index and the LifeSci Biotechnology Products Index, scheduled to go into effect at the market on on 12/16/2024.

25NOV

Removal of Component(s) - LBPH (Clinical Trials)

LifeSci Biotechnology Clinical Trials Index Effective at the market close on November 26, 2024, LBPH will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On October 14, 2026, LBPH announced it agreed to be acquired for $60.00/share in cash.

13JUN

Semi-Annual Reconstitution (Final) - June 2024

LifeSci Biotechnology Products Index LifeSci Biotechnology Clinical Trials Index Index Semi-Annual Reconstitution (Final) The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Monday, June 17, 2024. All positions will be equally weighted, with weights determined as of the closing prices on Friday, June 14, 2024. The preliminary changes are summarized below. LifeSci Biotechnology Clinical Trials Index (120 components as adjusted) Additions (34 stocks): ABUS, ANNX, APLT, ARQT, AUTL, AVTE, CATX, CELC, CGON, CNTA, CRGX, DNTH, ELVN, ERAS, EWTX, FULC, HLVX, IMNM, JANX, KYTX, LBPH, LRMR, NAMS, NGNE, NUVB, PHVS, PRAX, PRME, SLN, STOK, SVRA,

29MAY

Removal of Component(s) – INBX

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Wednesday, May 29, 2024, INBX will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On January 23, 2024, Inhibrx announced that it would be acquired by Sanofi for $30.00/share in cash and one CVR for up to $5.00/cash.

15MAY

Removal of Component(s) – ALPN

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Thursday, March 16, 2024, ALPN will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On April 10, 2024, Alpine Immune Sciences announced that it would be acquired by Vertex Pharmaceuticals for $65.00/share in cash.

14MAR

Removal of Component(s) – CBAY, KRTX

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Friday, March 15, 2024, CBAY and KRTX will be removed from the LifeSci Biotechnology Clinical Trials Index and their values will be redistributed to the remaining index components based on their weights. On December 22, 2023, Karuna Therapeutics, Inc. announced that it would be acquired by Bristol Myers for $330.00/share in cash. On February 12, 2024, CymaBay announced that it would be acquired by Gilead Sciences for $32.50/share in cash.

05MAR

Removal of Component(s) – AMAM

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Wednesday, March 6, 2024, AMAM will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On January 8, 2024, Ambrx announced that it would be acquired by Johnson & Johnson for $28.00/share in cash.

20FEB

Removal of Component(s) – RYZB

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Thursday, February 22, 2024, RYZB will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On December 26, 2023, RayzeBio, Inc. announced that it would be acquired by Bristol Myers for $62.50/share in cash.

10DEC

Semi-Annual Reconstitution (Preliminary) - December 2023

LifeSci Biotechnology Products Index LifeSci Biotechnology Clinical Trials Index The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Monday, December 18, 2023. All positions will be equally weighted, with weights determined as of the closing prices on Thursday, December 14, 2023. The preliminary changes are summarized below. LifeSci Biotechnology Clinical Trials Index (107 components as adjusted) Additions (17 stocks): ALPN, APGE, BEAM, BLTE, CABA, MGNX, NMRA, OLMA, ORIC, RYZB, SANA, SLNO, SLRN, SRRK, SYRE, TNGX, VERA Deletions (21 stocks): ABUS, ALDX, ARQT, ATAI, AVIR, BTAI, CERE, DSGN, ERAS, EWTX, FATE, FGEN, KOD, MCRB, MRSN, MRTX,

03NOV

Removal of Component(s) – PNT, ICPT

LifeSci Biotechnology Clinical Trials Index LifeSci Biotechnology Products Index Effective at the market close on Monday, November 6, 2023, the following changes will be made the LifeSci Biotechnology Indexes: PNT will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On October 3, 2023, Point Biopharma Global announced it would be acquired by Eli Lilly and Company for $12.50/share in cash. ICPT will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On September 26, 2023, Intercept

20SEP

Removal of Component(s) – RETA

LifeSci Biotechnology Products Index Effective at the market close on Thursday, September 21, 2023, RETA will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On July 28, 2023, Reata Pharmaceuticals announced that it would be acquired by Biogen Inc. for $172.50/share in cash.

07AUG

Removal of Component(s) – DICE

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Tuesday, August 8, 2023, DICE will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On June 20, 2023, DICE Therapeutics announced that it would be acquired by Eli Lilly for $48.00/share in cash.

14JUN

Semi-Annual Reconstitution (Final) - June 2023

LifeSci Biotechnology Products Index LifeSci Biotechnology Clinical Trials Index Index Semi-Annual Reconstitution (Final) The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Friday, June 16, 2023. All positions will be equally weighted, with weights determined as of the closing prices on Wednesday, June 14, 2023. The preliminary changes are summarized below. LifeSci Biotechnology Clinical Trials Index (115 components as adjusted) Additions (15 stocks): ALDX, AMAM, ARDX, BMEA, CBAY, ETNB, EXAI, GPCR, IRON, LQDA, MLTX, MLYS, PHAT, TERN, VKTX Deletions (21 stocks): ACET, AFMD, ALT, ALVR, ATRA, CARA, CCCC, CDXS, IMAB, INKT, INO, KZR, NGM, NKTX, NUVB, RPTX, SGMO

26APR

Removal of Component(s) – MYOV

LifeSci Biotechnology Products Index Effective at the market close on Wednesday, April 26, 2023, PRVB will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On March 13, 2023, Provention Bio announced that it would be acquired by Sanofi for $25.00/share in cash.

27FEB

Removal of Component(s) – MYOV

LifeSci Biotechnology Products Index Effective at the market close on Tuesday, February 28, 2023, MYOV will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On October 23, 2022, Myovant Sciences announced that it would be acquired by Sumitomo Pharma for $27.00/share in cash.